Anti-Mullarian Hormone As A Diagnostic Marker of Polycystic Ovary Syndrome


  • Shabana Abbas Department of Chemical Pathology, Foundation University Medical College, Islamabad Pakistan
  • Asma Hayat Department of Chemical Pathology, Combined Military Hospital, Jhelum/National University of Medical Sciences (NUMS) Pakistan
  • Rabiya Shabir Department of Obstetrics and Gynecology, Kharadar General Hospital, Karachi Pakistan
  • Muhammad Mujahid Sharif Department of Neurosurgery, Pakistan Institute of Medical Sciences, Islamabad Pakistan
  • Asma Iqbal Department of Obstetrics and Gynecology, Fauji Foundation Hospital, Rawalpindi Pakistan
  • Rehana Abbas Department of Dental Surgery, DHQ Hospital, Muzaffargarh Pakistan



Anti-mullerian hormone, Infertility, Obesity, Polycystic ovary syndrome


Objective: To determine the utility of Anti-mullerian hormone (AMH) as a diagnostic marker of Polycystic ovarian syndrome

Study Design: Comparative cross-sectional study

Place and Duration of the Study: Department of Chemical Pathology and Endocrinology, Army Medical College Rawalpindi, Pakistan in collaboration with the Department of Gynaecology and Obstetrics, Pak-Emirates Military Hospital, Rawalpindi Pakistan from Jan 2019 to Jan 2020.

Methodology: The study recruited 30 cases of PCOS and 30 age-matched Controls using Rotterdam criteria. Anti-mullerian
hormone (AMH) and testosterone were measured for both the study groups.

Results: Receiver operator curve (ROC) analysis confirmed the utility of anti-mullerian hormone in diagnosing patients with
PCOS. The AUC was 0.754 with 95% CI (0.629-0.880). The optimal cut-off point was 3.22ng/mL (Sensitivity 80%, Specificity

Conclusion: The AMH is appraised as an independent screening marker for PCOS patients. Using this single parameter can
decrease the patient's inconvenience and financial burden on the health care system and the patient.


Download data is not yet available.


Metrics Loading ...


Stracquadanio M, Ciotta L, Palumbo MA. Relationship between

serum anti-Mullerian hormone and intrafollicular AMH levels in

PCOS women. Gynecol Endocrinol 2018; 34(3): 223-228.

Bani Mohammad M, Majdi Seghinsara A. Polycystic Ovary

Syndrome (PCOS), Diagnostic Criteria, and AMH. Asian Pac J

Cancer Prev 2017; 18(1): 17-21.

Hoyos LR, Visser JA, McLuskey A, Chazenbalk GD, Grogan TR,

Dumesic DA. Loss of anti-Müllerian hormone (AMH)

immunoactivity due to a homozygous AMH gene variant

rs10417628 in a woman with classical polycystic ovary

syndrome (PCOS). Hum Reprod 2020; 35(10): 2294-2302.

Sahmay S, Aydogan Mathyk B, Sofiyeva N, Atakul N, Azemi A,

Erel T. Serum AMH levels and insulin resistance in women with

PCOS. Eur J Obstet Gynecol Reprod Biol 2018; 224: 159-164.

Vembu R, Reddy NS. Serum AMH Level to Predict the Hyper

Response in Women with PCOS and Non-PCOS Undergoing

Controlled Ovarian Stimulation in ART. J Hum Reprod Sci 2017;

(2): 91-94.

Saxena U, Ramani M, Singh P. Role of AMH as Diagnostic Tool

for Polycystic Ovarian Syndrome. J Obstet Gynaecol India 2018;

(2): 117-122.

Shrikhande L, Shrikhande B, Shrikhande A. AMH and Its

Clinical Implications. J Obstet Gynaecol India 2020; 70(5): 337-

Jamil Z, Fatima SS, Ahmed K, Malik R. Anti-Mullerian

Hormone: Above and Beyond Conventional Ovarian Reserve

Markers. Dis Markers 2016; 2016: 5246217.

Catteau-Jonard S, Dewailly D. Pathophysiology of polycystic

ovary syndrome: the role of hyperandrogenism. Front Horm Res

; 40: 22-27.

Abbara A, Eng PC, Phylactou M, Clarke SA, Hunjan T, Roberts

R, et al. Anti-Müllerian hormone (AMH) in the Diagnosis of

Menstrual Disturbance Due to Polycystic Ovarian Syndrome.

Front Endocrinol 2019; 10: 656.

Dewailly D. Diagnostic criteria for PCOS: Is there a need for a

rethink? Best Pract Res Clin Obstet Gynaecol 2016; 37: 5-11.

Shi Y, Li L, Zhou J, Sun J, Chen L, Zhao J, et al. Efficacy of

electroacupuncture in regulating the imbalance of AMH and

FSH to improve follicle development and hyperandrogenism in

PCOS rats. Biomed Pharmacother 2019; 113: 108687.

Amer SA, Shamy TTE, James C, Yosef AH, Mohamed AA. The

impact of laparoscopic ovarian drilling on AMH and ovarian

reserve: a meta-analysis. Reproduction 2017; 154(1): R13-R21.

Bhide P, Kulkarni A, Dilgil M, Dhir P, Shah A, Gudi A, et al.

Phenotypic variation in anti-Mullerian hormone (AMH)

production per follicle in women with polycystic ovary

syndrome (PCOS) and isolated polycystic ovarian morphology

(PCOM): an observational cross-sectional study. Gynecol

Endocrinol 2017; 33(10): 801-806.

Wiweko B, Indra I, Susanto C, Natadisastra M, Hestiantoro A.

The correlation between serum AMH and HOMA-IR among

PCOS phenotypes. BMC Res Notes 2018; 11(1): 114.

Peigné M, Pigny P, Pankhurst MW, Drumez E, Loyens A,

Dewailly D, et al. The proportion of cleaved anti-Müllerian

hormone is higher in serum but not follicular fluid of obese

women independently of polycystic ovary syndrome. Reprod

Biomed Online 2020; 41(6): 1112-1121.

Calzada M, López N, Noguera JA, Mendiola J, Hernández AI,

Corbalán S, et al. AMH in combination with SHBG for the

diagnosis of polycystic ovary syndrome. J Obstet Gynaecol 2019;

(8): 1130-1136.

Gupta M, Yadav R, Mahey R, Agrawal A, Upadhyay A,

Malhotra N, et al. Correlation of body mass index (BMI), antimullerian hormone (AMH), and insulin resistance among

different polycystic ovary syndrome (PCOS) phenotypes - a

cross-sectional study. Gynecol Endocrinol 2019; 35(11): 970-973.




How to Cite

Abbas, S., Hayat, A., Shabir, R., Sharif, M. M., Iqbal, A., & Abbas, R. (2024). Anti-Mullarian Hormone As A Diagnostic Marker of Polycystic Ovary Syndrome. Pakistan Armed Forces Medical Journal, 74(1), 188–191.



Original Articles

Most read articles by the same author(s)

1 2 > >>